1551355-46-4
1551355-46-4 structure
- Name: Simmiparib
- Chemical Name: Simmiparib
- CAS Number: 1551355-46-4
- Molecular Formula: C23H18F4N6O2
- Molecular Weight: 486.431
- Catalog: Signaling Pathways Cell Cycle/DNA Damage PARP
- Create Date: 2020-01-16 13:33:24
- Modify Date: 2024-02-04 11:32:50
-
Simmiparib is a novel potent, orally active PARP1/2 inhibitor with IC50 of 1.75/0.22 nM, inhibits PARP1 >90-fold more potently than the other PARPs (PARP3, TNKS1, TNKS2); selectively induces the accumulation of DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination repair (HR)-deficient cells; potentiates the proliferative inhibition of several conventional anticancer drugs, reduces the poly(ADP-ribose) formation in HR-deficient cancer cells and xenografts; exhibits 10-fold greater growth inhibition than olaparib against HR-deficient human cancer cell- or tissue-derived xenografts in nude mice. Solid Tumors Phase 1 Clinical
| Name | Simmiparib |
|---|
| Description | Simmiparib is a novel potent, orally active PARP1/2 inhibitor with IC50 of 1.75/0.22 nM, inhibits PARP1 >90-fold more potently than the other PARPs (PARP3, TNKS1, TNKS2); selectively induces the accumulation of DNA double-strand breaks, G2/M arrest and apoptosis in homologous recombination repair (HR)-deficient cells; potentiates the proliferative inhibition of several conventional anticancer drugs, reduces the poly(ADP-ribose) formation in HR-deficient cancer cells and xenografts; exhibits 10-fold greater growth inhibition than olaparib against HR-deficient human cancer cell- or tissue-derived xenografts in nude mice. Solid Tumors Phase 1 Clinical |
|---|---|
| References | References 1. Yuan B, et al. Cancer Lett. 2017 Feb 1;386:47-56. 2. Yang ZM, et al. Acta Pharmacol Sin. 2017 Jul;38(7):1038-1047. View Related Products by Target PARP Solid Tumors |
| Molecular Formula | C23H18F4N6O2 |
|---|---|
| Molecular Weight | 486.431 |